Novo Faces Narrowed Investor Suit Over Obesity Drug Claims
By Carla Baranauckas · July 29, 2026, 8:03 PM EDT
A New Jersey federal judge narrowed a proposed securities class action against Novo Nordisk, preserving claims that it misled investors about the CagriSema obesity drug's tolerability and a flexible protocol used...
To view the full article, register now.